Calgary, Canada – TheNewswire – April 7, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (OTC: VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, announces that it has issued 191,490 Deferred Share Units ("DSUs") to directors of the Corporation pursuant to its fixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one common... Read More

Calgary, Alberta, Canada – April 1, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (" Voyageur " or the " Company ") is pleased to announce the successful completion of a key phase in human testing of its Health Canada-licensed barium contrast media product suite. This milestone paves the way for Voyageur’s upcoming product launch across the Candain market. A total of 24 test subjects... Read More

Calgary, Alberta, Canada – March 4, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“Voyageur” or the “Company”) is pleased to announce the commencement of the Frances Creek barium contrast media project, powered by a $600,000 grant from Alberta Innovates. With $350,000 in funding already released, Voyageur has commenced processing the high-grade Frances Creek ore samples, to produce natural,... Read More

Calgary, Alberta--(Newsfile Corp. - March 3, 2025) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") wishes to clarify the terms of a distribution and wholesaling agreement (the " Agreement ") it previously announced on May 28, 2024, and referred to subsequently in news releases dated January 15 and 23, 2025. On May 28, 2024, the Company issued a news release in which it announced the... Read More

Calgary, Alberta, Canada – February 18, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) (OTC Pink:VYYRF) ("Voyageur" or the "Company") is pleased to announce the launch of its next generation MRI contrast agent development program in collaboration with Applied Pharmaceutical Innovations ( API ) and Rain Cage... Read More

Voyageur receives $600,000 in funding through Alberta Innovates AICE-Market Access Program Calgary, Alberta, Canada – February 5, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”) is excited to announce its receipt of a $600,000 grant from Alberta Innovates (“ Alberta Innovates ”), a provincial Crown corporation and Alberta’s largest research and innovation... Read More

Voyageur streamlines capitalization table through exercise of 5,725,829 warrants, expiry of 8,844,935 warrants Strong existing shareholder support, raising gross proceeds of $687,099 Calgary, Alberta, Canada – January 23, 2025 – TheNewswire - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (“ Voyageur ” or the “ Company ”), a company planning to vertically integrate the medical imaging industry, is pleased to... Read More

LOI with Multinational Contrast Media Company Voyageur Introduced Five New Health Canada Licensed Barium Contrast Products Securing 1st Sales Contract Calgary, Alberta, Canada – TheNewswire - January 1 5 , 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (" Voyageur " or the " Company "), a company vertically integrating the medical imaging industry, is pleased to recap a series of achievements and upcoming... Read More

Calgary, Alberta, Canada – TheNewswire - January 13, 2025 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (OTC Pink:VYYRF) (" Voyageur " or the " Company ") is pleased to announce that it has begun human testing on its latest barium contrast suite of products (as outlined below). This is a necessary and critical step for the Company, as it marks another milestone in the Company’s path forward towards market launch. Five of the... Read More

LOI Agreement is steppingstone to formal agreement, The Multinational Pharmaceutical company is ranked in the top five contrast agent suppliers in the world, signaling and solidifying Voyageur’s importance in the global contrast agent market Calgary, Alberta, Canada – TheNewswire - December 20, 2024 - Voyageur Pharmaceuticals Ltd. ( TSXV:VM ) ( OTC Pink:VYYRF) ("Voyageur" or the "Company") a vertically integrated radiology... Read More

Calgary, Alberta, Canada, December 18, 2024 – TheNewswire - Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) (" Voyageur " or the " Corporation "), is pleased to announce that, further to its news releases of October 17, November 26, and December 3, 2024, the Corporation has completed the second and final tranche closing (the " Final Closing ") of its previously announced non-brokered private placement of units ("... Read More

Calgary, Alberta, Canada, December 3, 2024 – TheNewswire - Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) (" Voyageur " or the " Corporation "), is pleased to announce that, further to its news releases of October 17 and November 26, 2024, the Corporation has completed the first tranche closing (the " First Closing ") of its previously announced non-brokered private placement of units (" Units ") at a price of... Read More

Calgary, Alberta--(Newsfile Corp. - October 17, 2024) - Voyageur Pharmaceuticals Ltd . (TSXV: VM) (OTC Pink: VYYRF) (" Voyageur " or the " Corporation "), is pleased to announce a proposed non-brokered private placement of up to 16,666,667 units (" Units ") at a price of $0.06 per Unit, for gross proceeds of up to CND$1,000,000 (the " Offering "). There is no minimum Offering. Each Unit shall be comprised of one common share... Read More

Calgary, Alberta--(Newsfile Corp. - September 25, 2024) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) ("Voyageur" or the "Company") announces that it has granted an aggregate of 600,000 stock options (the "Options") to officers of the Company pursuant to its incentive stock option plan. The Options were granted at an exercise price of $0.06 per share, vest immediately, and have a 10-year term. The Options are... Read More

Calgary, Alberta, Canada – TheNewswire - September 24, 2024 - Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") is pleased to announce the appointment of Dr. Ibrahim Hashmi as Vice President of Business Development, as key strategic move that signals the company’s commitment to accelerating its commercial initiatives and expanding its global footprint in the medical imaging industry. Dr.... Read More

Calgary, Alberta, Canada, September 17, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") proudly announces the appointment of Dr. Iryna Saranchova M.D., Ph.D., as its new Chief Science Officer (CSO), pending regulatory approval. Dr. Saranchova, a distinguished expert in clinical research and immunology, brings a wealth of experience that will further accelerate the... Read More

Calgary, Alberta, Canada, September 5, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") announces that in an innovative endeavor, it has completed formulation work on its new product line of 5 Health Canada licensed products. Voyageur has engineered these advanced formulations to improve existing market standards, prioritizing enhanced value for stakeholders. By... Read More

Calgary, Alberta, Canada, June 11, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") announces that in an innovative endeavor, Voyageur and Rain Cage Carbon Inc. ("Rain Cage") are following up on the first commercial creation of a V@C 60 endohedral fullerene (Vanadium atom inside a C 60 molecule). Rain Cage is now embarking on the next phase of radiology drug... Read More

Calgary, Canada, May 28, 2024 – TheNewswire – Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Company") proudly announces its first international distribution agreement with a sales commitment of USD $1.9 million ( CAD $2.6M ), over the first three (3) years of commercialization. The agreement is with a company specializing in the sale of radiology products in Latin America. This initial agreement... Read More

Calgary, Alberta, Canada / TheNewswire / March 26, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) (" Voyageur " or the " Company "), announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2023 on SEDAR+. Option Grant Voyageur also announces that it has granted 3,700,000 stock options (the " Options ") to directors,... Read More

Voyageur Pharmaceuticals Ltd . ( TSX.V: VM ) (USA: VYYRF) ("Voyageur" or the "Corporation"), announces a significant advancement in its partnership with Rain Cage Carbon Inc. ("Rain Cage"). This milestone signifies the execution of a royalty agreement that solidifies the exclusive development and license agreement between the parties and it further reinforces Voyageur’s commitment to pioneering sustainable carbon drug... Read More

Voyageur Pharmaceuticals Ltd . (TSX.V: VM) (USA: VYYRF) ("Voyageur" or the "Corporation") and Applied Pharmaceutical Innovation (API), a leading industry-funded not-for-profit organization driving life sciences commercialization, proudly announce the signing of a Master Services Agreement ( MSA ). This collaboration represents a significant advancement in both entities’ commitment to innovation, heralding a transformative... Read More

Calgary, Canada / TheNewswire / March 1, 2024 - Voyageur Pharmaceuticals Ltd . ( TSX.V:VM ) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce it has closed its previously announced (January 16, 2024) non-brokered private placement (the "Offering") of units ("Units") sold at a price of $0.08 per Unit. Pursuant to the Offering, the Company issued 6,106,250... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) (USA:VYYRF) ("Voyageur" or the "Company"), a provider of innovative medical imaging solutions, is pleased to announce a proposed non-brokered private placement of up to 10,000,000 units ("Units") at a price of $0.08 per Unit, for gross proceeds of up to CND$800,000 (the "Offering"). Each Unit shall be comprised of one common share in the capital of the Company (each, a "Common... Read More

Calgary, Canada - TheNewswire - December 21, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is excited to announce that its carbon capture and drug development partner, Rain Cage Carbon Inc. (“Rain Cage”), has successfully completed Stage 1 testing of a new molecule, metallofullerene, for the medical imaging industry. This... Read More

Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) (USA:VYYRF) (" Voyageur " or the " Corporation "), a provider of innovative medical imaging solutions, is pleased to announce the formalization of a pivotal sales and distribution alliance with an internationally recognized pharmaceutical distribution company in Central America. This landmark agreement marks a significant milestone in Voyageur's journey, signaling its entry into the... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the completion of formulation and the engineering for production processing for the dry powdered barium contrast media product HDXBa TM . HDXBa TM is an oral contrast agent for suspension used as an oral drug for use in double-contrast radiographic... Read More

Calgary, Alberta - TheNewswire - August 1, 2023 - Voyageur Pharmaceuticals Ltd. ( TSX.V:VM ) ( USA: VYYRF ) (the " Company " or " Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended May 31, 2023 on SEDAR+ (www.sedarplus.ca). Voyageur also announces the retirement from the Board of Directors of the Corporation (the " Board ") of Ron Sifton who... Read More

Calgary, Alberta - TheNewswire - July 13, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that on July 10, 2023, it issued 383,360 Deferred Share Units ("DSUs") to directors of the Company pursuant to its fixed 10% equity incentive compensation plan (the "Plan"). Each DSU represents a right of the holder to receive one common share ("Common Share") of the Company... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( USA : VYYRF) ("Voyageur" or the "Corporation"), a provider of innovative medical imaging solutions, is pleased to announce the release of the white paper titled "SmoothX: A Promising New Positive Oral Contrast Agent for CT." Authored by Alec J. Megibow, MD, MPH, FACR, the white paper highlights the remarkable imaging properties of Voyageur's product, SmoothX™, emphasising its... Read More

Voyageur Pharmaceuticals Ltd . ( TSXV:VM ) ( OTC :VYYRF) ("Voyageur" or the "Corporation"), announces it has entered into a groundbreaking development and license agreement with Rain Cage Carbon Inc. ("Rain Cage"). This strategic partnership aims to revolutionize the field by developing and manufacturing cutting-edge nanocarbon/fullerene-based contrast agents for medical imaging, utilizing Rain Cage’s innovative EDEN™ carbon... Read More

Calgary, AB - TheNewswire - April 28, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that it has filed its interim financial statements and management's discussion and analysis for the quarter ended February 28, 2023 on SEDAR. The Company also announces that on April 10, 2023, it issued 328,675 Deferred Share Units ("DSUs") to directors of the Company pursuant to its... Read More

Calgary, Alberta – TheNewswire - April 4, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces that it has completed comparative studies of SmoothX® versus Readi-Cat ® 2% with taste test and Computed Tomography (CT) scans on patients. Results of the double-blind testing showed that SmoothX® was favoured on drinkability and taste by 75% of patients compared to the competing... Read More

Calgary, AB - TheNewswire - March 30, 2023 - Voyageur Pharmaceuticals Ltd. (TSX.V:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has filed its annual audited financial statements and management's discussion and analysis for the year ended November 30, 2022 on SEDAR. The Company also announces that, due to a shortfall in spending on the Frances Creek project, because of closures to the site over the past... Read More

Calgary, Alberta – TheNewswire - February 14, 2023 - Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") continues to advance its sales and marketing programs and is preparing to launch its first product, SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market, in Canada. Voyageur announced today that Ethan Mohan has joined the Company’s sales team as Canadian Sales... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the " Company " or " Voyageur ") announces that, further to its news releases dated December 8 and 23, 2022 and January 12 and 20, 2023, the use of proceeds with respect to its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), were incorrectly totalled. The gross proceeds received by Voyageur from... Read More

Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 8 and 23, 2022 and January 12, 2023, it has completed the second and final closing of its increased non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit (the " Offering "), issuing an aggregate of 14,570,764 Units for gross... Read More

News Release – TheNewswire - Calgary, Alberta – January 12, 2023: V oyageur Pharmaceuticals Ltd. (TSXV:VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news releases dated December 6 and 23, 2022, and due to strong investor demand for its non-brokered private placement of units of the Company (" Units ") at a price of $0.07 per Unit, it has increased the maximum size of the... Read More

News Release – Calgary, Alberta – TheNewswire - December 23, 2022: Voyageur Pharmaceuticals Ltd. (TSX.V: VM) (USA: VYYRF) (the " Company " or " Voyageur ") is pleased to announce that, further to its news release dated December 6, 2022, it has completed the first closing of its non-brokered private placement of up to units of the Company (" Units ") for proceeds of up to CDN$650,000, with each Unit being sold at a price of... Read More

News Release – Calgary, Alberta – TheNewswire - December 8, 2022: Voyageur Pharmaceuticals Ltd. (TSXV:VM) (USA:VYYRF) (the "Company" or "Voyageur") announces that it has initiated its marketing campaign to introduce SmoothX ™ barium sulfate CT contrast media, to the CT Imaging market in Canada. SmoothX is a generic oral barium sulfate contrast media product, designed to assist in diagnosing disease using computed tomography... Read More

Calgary, Alberta--(Newsfile Corp. - December 2, 2022) - Voyageur Pharmaceuticals Ltd. (TSXV: VM) (OTC Pink: VYYRF) (the "Company" or "Voyageur") announces that it has issued 125,322 Deferred Share Units ("DSUs") to directors pursuant to its fixed 10% equity incentive compensation plan adopted by the Company following receipt of shareholder approval on June 28, 2021 (the "Plan"). Each DSU represents a right of the holder to... Read More

Calgary, Alberta – TheNewswire - November 28, 2022 : Voyageur Pharmaceuticals Ltd. (TSXV:VM) ( OTC :VYYRF) (the "Company" or "Voyageur") announces completion of the production test batch of its SmoothX™ barium sulfate CT contrast media oral suspension for the CT imaging market in Canada. This development represents a significant transition for Voyageur from the development phase to the production phase, where the focus will... Read More